According to the Xinhua Pharmaceutical announcement, the cumulative deviation value of the closing price increase of the company's A-share shares reached 20% for three consecutive trading days on September 18, September 21, and September 22, 2026, which is an abnormal fluctuation in stock trading. Recently, the company has successively disclosed announcements relating to three drug registration certificates, including azithromycin tablets passing the generic drug consistency evaluation and obtaining a concentrated solution of magnesium, sodium, and potassium sulfate for oral administration. After verification, there was no need to correct or supplement the information disclosed earlier by the company. There were no major changes in the business situation or internal and external business environment, no major matters to be disclosed by the controlling shareholders or actual controllers, and the company's shares were not traded during the change period. The company reminds investors to pay attention to the risk of stock price fluctuations in the secondary market and invest rationally.

According to the Xinhua Pharmaceutical announcement, the cumulative deviation value of the closing price increase of the company's A-share shares reached 20% for three consecutive trading days on September 18, September 21, and September 22, 2026, which is an abnormal fluctuation in stock trading. Recently, the company has successively disclosed announcements relating to three drug registration certificates, including azithromycin tablets passing the generic drug consistency evaluation and obtaining a concentrated solution of magnesium, sodium, and potassium sulfate for oral administration. After verification, there was no need to correct or supplement the information disclosed earlier by the company. There were no major changes in the business situation or internal and external business environment, no major matters to be disclosed by the controlling shareholders or actual controllers, and the company's shares were not traded during the change period. The company reminds investors to pay attention to the risk of stock price fluctuations in the secondary market and invest rationally.